{"filings":[{"id":1065516,"accession_number":"0001140361-26-025324","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-06-16T10:30:49+00:00","items":["5.07"],"status":"ready","headline":"Gyre Therapeutics stockholders elect directors, approve executive pay, auditor, and Series B conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class II directors David M. Epstein, Ph.D. and Dan Weng, M.D. re-elected with ~70.2M and ~70.5M votes for, respectively.","Non-binding advisory vote on executive compensation approved with 70.5M votes for, 34,907 against.","Ratification of Grant Thornton Zhitong as independent auditor for FY2026 approved with 72.5M votes for.","Approval of conversion of Series B Convertible Preferred Stock into common stock passed with 70.5M votes for.","Broker non-votes reported for all proposals except auditor ratification (none)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":786996,"accession_number":"0001140361-26-023625","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-06-02T10:09:32+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics posts updated corporate presentation; specific content not available in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated June 2026 made available on company's website on June 1, 2026.","Presentation describes Gyre as a biopharma company focused on fibrosis, inflammatory diseases, and cancer.","Filing includes only the title slide; full presentation content is not included in the provided exhibit text.","Investors should refer to the full presentation on the company's website for detailed updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":445199,"accession_number":"0001140361-26-021360","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-05-14T21:25:34+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics to Present at Shanghai Scientific Conference on May 15, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gyre Therapeutics (GYRE) will present at a scientific conference in Shanghai on May 15, 2026.","Presentation covers the company's focus on fibrosis, inflammatory diseases and cancer.","Exhibit 99.1 furnished under Item 7.01 of Form 8-K, dated May 2026.","Regulation FD disclosure; presentation not deemed filed for SEC liability purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":42441,"accession_number":"0001140361-26-020845","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-05-12T21:03:02+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics' NDA for F351 accepted by China's NMPA for CHB-induced liver fibrosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA for F351 (hydronidone) accepted by CDE of China's NMPA for chronic hepatitis B-induced liver fibrosis.","NMPA granted priority review status in March 2026; this is Gyre's first NDA for the F351 program.","If approved, F351 could address tens of millions of HBV patients in China at risk of fibrosis and cirrhosis.","Dr. Ying Luo noted positive CDE interactions and the potential of F351 as an innovative therapeutic option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91422,"accession_number":"0001193125-26-209789","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gyre Therapeutics Q1 revenue $22.5M, net loss $9.9M; Cullgen acquisition closed; NDA for F351 submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $22.5M (+2% YoY); GAAP basic EPS $(0.10); net loss $9.9M vs $3.7M net income YoY.","Non-GAAP adjusted net loss $4.2M vs adjusted net income $2.9M in Q1 2025.","Completed acquisition of Cullgen for ~$300M all-stock, expanding pipeline into inflammatory diseases and cancers.","NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China's CDE in March 2026 with priority review.","FY 2026 revenue guidance reaffirmed at $100.5-$111.0M; first patient enrolled in Phase 2/3 trial for radiation-induced lung injury."],"consensus_eps_estimate":-0.0748,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":22519000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91421,"accession_number":"0001140361-26-018716","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.01","5.03","1.01","3.02","3.03","5.02","7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics completes $300M all-stock acquisition of Cullgen; appoints Ying Luo as CEO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-stock deal valued at ~$300M closed; Cullgen becomes wholly owned subsidiary.","Ying Luo appointed CEO and President; Ping Zhang remains Chairman.","Combined company has commercial ETUARY® in China for lung fibrosis and late-stage pipeline including F351 for liver fibrosis.","Cullgen contributes targeted protein degrader (TPD) and degrader-antibody conjugate (DAC) pipeline.","Company will hold stockholder meeting June 10, 2026 for approval of conversion of Series B Preferred to common."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91420,"accession_number":"0001140361-26-015307","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K/A","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Gyre Therapeutics amends 8-K to correct Cullgen stock conversion terms in $300M acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment fixes clerical error in original March 2, 2026 8-K describing stock conversion for Cullgen holders.","Designated Cullgen shareholders receive Series B Convertible Preferred, convertible into 5 Gyre common shares each.","Other Cullgen holders receive Gyre common stock at exchange ratio of 0.4753 per Cullgen share.","All-stock deal values Cullgen at ~$300 million; no substantive changes to merger agreement beyond correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101488,"accession_number":"0001140361-26-010654","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gyre Therapeutics subsidiary submits NDA in China for F351 for CHB-induced liver fibrosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Gyre's majority-owned subsidiary Gyre Pharmaceuticals submitted NDA to China's CDE for lead candidate F351 (Hydronidone).","F351 is for treatment of chronic hepatitis B (CHB)-induced liver fibrosis.","NDA subject to formatting verification; CDE will issue acceptance number before technical review.","Company will work with CDE on supplementary materials if requested."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101487,"accession_number":"0001193125-26-102700","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gyre Therapeutics FY2025 revenue up 10% to $116.6M; net income down; guides FY2026 lower","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $116.6M (+10.2% YoY); net income $9.9M vs $17.9M; non-GAAP adj. net income $18.9M vs $16.9M.","Q4 2025 revenue $37.2M (+33.3% YoY); net loss $1.4M vs income $0.6M; non-GAAP adj. net income $4.3M vs $1.1M.","FY2026 revenue guidance $100.5M–$111.0M, a decline of 4.8%–13.8% vs 2025, citing regulatory priorities and market dynamics.","Agreed to acquire Cullgen in ~$300M all-stock deal; transaction expected to close Q2 2026, adding protein degrader platform.","Hydronidone NDA for conditional approval in China (CHB fibrosis) planned H1 2026; U.S. IND for MASH fibrosis targeted in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101486,"accession_number":"0001140361-26-009115","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Gyre Therapeutics projects $400-600M in F351 revenue within 5 years; provides Cullgen TRK degrader update","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company sees potential $400-600M revenue for Hydronidone (F351) in liver fibrosis within 5 years.","Expects ETUARY for lung fibrosis to sustain ~$100M absent near-term generic competition.","Sees 20-25% net margins for commercial products; favorable R&D tax deductibility in Beijing/Shanghai campuses.","Cullgen's TRK degrader CG001419 Phase 2 pain trial enrolling at doses expected to show ~95% TRK degradation.","Cullgen's degrader antibody conjugates (DAC) show ~10-100x potency vs standalone degrader in vitro/animal models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101485,"accession_number":"0001140361-26-007249","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","5.03","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Gyre acquires Cullgen for ~$300M in stock; gains TPD/DAC platform, new CEO appointed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-stock acquisition values Cullgen at ~$300M; expected close early Q2 2026; Cullgen becomes wholly owned subsidiary.","Ying Luo (Cullgen CEO) appointed CEO/President and director of Gyre; Ping Zhang remains Executive Chairman; Thomas Eastling and Songjiang Ma resign from board.","Combined entity has commercial ETUARY® (lung fibrosis, China) and Hydronidone (F351) nearing NDA, plus Cullgen's preclinical/clinical TPD/DAC pipeline.","Issuance of Series B Convertible Preferred Stock; conversion requires stockholder approval; insiders subject to 180-day to 18-month lock-up agreements.","Support agreements from key Gyre and Cullgen stockholders to vote in favor of conversion proposal and merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101484,"accession_number":"0001140361-26-000253","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics aligns with China's CDE on Hydronidone conditional approval pathway after Pre-NDA meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CDE agreed existing Phase 3 data for Hydronidone supports conditional approval NDA for CHB-associated liver fibrosis.","CDE indicated Hydronidone meets priority review criteria; NDA submission planned for H1 2026.","Company will conduct a confirmatory Phase 3c trial to support conversion from conditional to regular approval.","Previously reported Phase 3 met primary endpoint: 52.85% treated vs 29.84% placebo achieved ≥1-stage fibrosis regression (p=0.0002)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117843,"accession_number":"0001193125-25-270524","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gyre Therapeutics reports Q3 2025 net income of $5.9M, cuts FY revenue guidance to $115-118M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $30.6M (+20% YoY), net income $5.9M (doubled), adjusted net income $8.8M.","Full-year revenue guidance lowered to $115-118M from $118-128M due to Etorel rollout delays.","Nine-month 2025 revenue $79.4M, net income $11.2M vs $17.3M YoY; basic EPS $0.08.","Cash $80.3M as of Sept 30; completed Phase 3 pneumoconiosis trial enrollment (272 patients).","Hydronidone NDA in China progressing; US IND for MASH delayed to 2026."],"consensus_eps_estimate":0.0272,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":79393000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134292,"accession_number":"0001140361-25-034506","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Gyre Therapeutics posts corporate presentation; no material financial or pipeline details provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted on company website as of Sept 10, 2025.","Presentation prepared for H.C. Wainwright Global Investment Conference in September 2025.","Filing text and exhibit excerpt do not disclose any new financial data or pipeline milestones.","Company focus remains anti-fibrotic therapeutics for chronic organ diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134291,"accession_number":"0001140361-25-032295","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics appoints Dan Weng, M.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dan Weng appointed as Class II director effective August 18, 2025.","Dr. Weng has extensive CRO leadership, including CEO of Medelis and former Chairman/CEO of EPS International.","Appointment supported by parent company GNI Group Ltd. (TSE: 2160).","He will receive standard non-employee director compensation per company policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134290,"accession_number":"0000950170-25-106525","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics Q2 revenue $26.8M (+6% YoY); net income falls to $1.6M; CEO transition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income of $1.6M ($0.00 EPS) vs $4.5M in Q2 2024; H1 net income $5.3M vs $14.5M.","Revenue Q2 $26.8M, up from $25.2M; H1 $48.8M, down from $52.4M due to ETUARY decline and new product launches.","Full-year revenue guidance reaffirmed at $118-128M (11-21% growth). Non-GAAP adj. net income Q2 $2.9M vs $3.1M.","CEO Han Ying resigned, becomes SVP Science; Executive Chair Ping Zhang appointed interim CEO.","Pipeline: Positive Phase 3 Hydronidone data; NDA filing with NMPA expected Q3 2025. Launched Etorel in June."],"consensus_eps_estimate":0.0306,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":48829000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151088,"accession_number":"0001140361-25-021612","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Gyre Therapeutics reports shareholder meeting results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Gordon Carmichael, Ph.D., elected as Class I director with 69,249,334 votes for, 297,881 withheld.","Songjiang Ma elected with 69,385,506 votes for, 161,709 withheld; Ping Zhang with 69,320,687 for, 226,528 withheld.","Non-binding advisory vote on executive compensation approved: 69,505,961 for, 39,318 against, 1,936 abstained.","Ratification of Grant Thornton Zhitong as independent auditor for FY2025 approved: 72,175,754 for, 3,738 against, 146,263 abstained.","Total shares entitled to vote: 93,742,602; broker non-votes reported for director elections and compensation vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151087,"accession_number":"0001140361-25-020353","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Gyre Therapeutics raises $20M in public offering for Phase 2 F351 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,222,222 shares at $9.00/share; underwriters have 30-day option for 333,333 additional shares.","Net proceeds estimated at $18.5M after discounts and expenses.","Funds U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis, R&D, and working capital.","Offering expected to close May 27, 2025; Jefferies LLC is sole book-running manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151086,"accession_number":"0001140361-25-020157","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gyre's Hydronidone meets Phase 3 primary endpoint with 52.85% fibrosis regression vs 29.84% placebo (p=0.0002)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial met primary endpoint: ≥1-stage Ishak fibrosis regression at Week 52 (52.85% vs 29.84%, p=0.0002).","NDA submission to China's NMPA expected in Q3 2025; Breakthrough Therapy designation granted in 2021.","U.S. Phase 2 trial in MASH-associated fibrosis to begin in 2H2025; IND planned for Q3 2025.","Safety comparable to placebo: 4.88% serious AEs vs 6.45%; no discontinuations due to AEs.","248 patients enrolled across 39 hospitals in China; key secondary endpoint also statistically significant (p=0.0246)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151085,"accession_number":"0000950170-25-067452","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gyre Therapeutics Q1 net income $3.7M, revenue $22.1M; reaffirms FY2025 guidance $118–128M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $3.7M ($0.03 basic EPS) vs $9.9M in Q1 2024; revenue $22.1M, down 19% due to ETUARY decline from prior year one-time campaign.","FY2025 revenue guidance reiterated at $118–128M (2024: $105.8M); commercial launches of nintedanib (May 2025) and avatrombopag (March 2025) expected to drive H2 growth.","Phase 3 Hydronidone trial for CHB liver fibrosis completed data lock; topline results expected Q2 2025. IND approved for pirfenidone for radiation-induced lung injury.","Non-GAAP adjusted net income $2.9M vs $8.2M; cash $51.3M as of March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":22058000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151084,"accession_number":"0001140361-25-015880","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics posts updated corporate presentation; no material financial disclosures","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Presentation titled 'Developing Anti-Fibrotic Therapeutics for Chronic Organ Diseases' made available on company website.","No new financial data, guidance, or clinical trial results disclosed in the filing or exhibit.","Presentation is furnished under Regulation FD; not deemed filed for SEC purposes.","Company continues to focus on fibrotic disease therapies; no changes to strategy announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169977,"accession_number":"0000950170-25-040232","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gyre Therapeutics reports FY2024 revenue $105.8M, issues FY2025 guidance $118-128M; Phase 3 data due Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue $105.8M (down 6.8% YoY); net income $17.9M vs loss $85.5M in 2023 on absence of IPR&D charge.","Non-GAAP adjusted net income $16.9M (down from $25.4M); cash $51.2M at year-end.","FY2025 revenue guidance $118-128M (11-21% growth) driven by planned launches of nintedanib and avatrombopag in China.","Pivotal Phase 3 trial of F351 in CHB-associated liver fibrosis topline data expected Q2 2025; U.S. Phase 2 in MASH planned.","Appointed Ping Zhang as lead independent director; Songjiang Ma appointed Chairman of Gyre Pharmaceuticals board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169976,"accession_number":"0001140361-25-004957","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"GNI Group FY2024 revenue down 9.2%, operating profit plunges 89.3%; Gyre pipeline catalysts set for 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue ¥23,611M (-9.2% YoY); operating profit ¥1,402M (-89.3%); pre-tax profit ¥238M (-98.1%).","Net loss attributable to owners of parent ¥977M (vs. ¥8,094M profit in FY2023); basic EPS ¥19.55 (vs. ¥169.50).","Operating cash flow negative ¥3,164M; investing cash outflow ¥10,361M; cash position ¥10,115M.","Gyre Pharms: Hydronidone Phase 3 topline data expected Q1 2025; F573 Ph2 completion, F230 Ph1 start planned.","F528 IND submission targeted for Dec 2025; GNI Group forecasts FY2025 revenue ¥28,733M (+21.7% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":105757000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169975,"accession_number":"0001140361-25-000292","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics chairman Ying Luo resigns; Ping Zhang appointed as lead independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ying Luo resigned as Chairman and Board member (eff. Dec 31, 2024) to focus on other responsibilities at GNI Group Ltd.","Ping Zhang appointed Class I director, lead independent director, and Nominating Committee member (eff. Jan 5, 2025).","Songjiang Ma appointed Chairman of Gyre Pharmaceuticals Board (eff. Jan 6, 2025).","Zhang is Managing Partner of String Capital and serves on the boards of GNI and Asian Star Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187020,"accession_number":"0001140361-24-047980","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Gyre Therapeutics enters $50M at-the-market equity offering with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement filed Nov 27, 2024; up to $50M of common stock may be sold.","Jefferies LLC acts as sales agent; commission up to 3.0% of gross proceeds.","Proceeds intended for R&D, manufacturing, scale-up, and general corporate purposes.","Sales may be made on Nasdaq under effective S-3 shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187019,"accession_number":"0000950170-24-125869","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gyre Therapeutics Q3 2024 revenue down 20% to $25.5M; net income falls to $2.9M from $7.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $25.5M in Q3 2024 vs $32.0M in Q3 2023, down 20% due to lower anti-fibrosis drug sales.","Net income $2.9M in Q3 2024 vs $7.5M in Q3 2023; nine-month net income $17.3M vs $15.5M.","Phase 3 trial for F351 in CHB liver fibrosis completed; topline data expected Q1 2025. US Phase 2 for MASH in 2025.","Commercial launches of avatrombopag (H1 2025) and nintedanib (2025) in China expected.","Cash and equivalents $15.9M as of Sept 30, 2024; funding runway over 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":77885000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203555,"accession_number":"0000950170-24-095687","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gyre Therapeutics Q2 revenue down 14% to $25.2M, net income up to $4.5M; receives NMPA approval for avatrombopag","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $25.2M (-14% YoY) on normalized ETUARY sales; net income $4.5M vs $3.8M YoY.","H1 revenue $52.4M (-3.5% YoY); net income $14.5M vs $8.0M YoY, driven by lower costs.","Received NMPA approval for avatrombopag for CLD thrombocytopenia (July 2024); expanded rare disease portfolio.","IND approved for F230 in PAH; Phase 3 F351 CHB data expected early 2025; U.S. IND for F351 in MASH by end 2024.","Appointed David M. Epstein to Board; cash and investments ~$54M, sufficient for 12+ months."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":52397000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203554,"accession_number":"0001140361-24-036404","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Gyre Therapeutics appoints David M. Epstein, Ph.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Epstein appointed as Class II director effective Aug 6, 2024; serves on Audit and Compensation Committees.","Epstein co-founded Black Diamond Therapeutics (BDTX) and PairX Bio; former CSO of OSI Pharmaceuticals.","Rodney Nussbaum appointed as Chair of Audit Committee on same date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203553,"accession_number":"0001140361-24-032511","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Director resigns; Nasdaq confirms Gyre out of compliance on audit committee composition","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nassim Usman resigned from Board and Audit Committee, effective June 30, 2024, not due to any disagreements.","On July 2, Nasdaq notified Gyre of non-compliance with Listing Rule 5605 (audit committee independence requirements).","Cure period runs until earlier of next annual meeting or June 30, 2025; company is recruiting a new independent director.","Company intends to reestablish compliance within cure period and avoid delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220020,"accession_number":"0001140361-24-030348","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Gyre Therapeutics shareholders approve officer exculpation amendment, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class III nominees elected: Thomas Eastling (68.9M for), Renate Parry (69.1M), Rodney Nussbaum (69.1M).","Advisory vote on executive compensation approved with 69.1M for, 7,487 against.","Ratification of Grant Thornton as auditor for FY 2024 passed (69.4M for, 7,601 against).","Amendment to certificate of incorporation extending exculpation to certain officers approved (69.0M for).","Certificate of amendment filed with Delaware on June 14, 2024, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220019,"accession_number":"0001140361-24-028106","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gyre subsidiary receives China NMPA IND approval for F230 in pulmonary arterial hypertension","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IND approved by CDE of China's NMPA for F230 tablets, a selective endothelin receptor antagonist for PAH.","F230 originally licensed from Eisai through Gyre's indirect stockholder GNI Group Ltd.","Preclinical data showed statistically significant reductions in mean pulmonary artery pressure and right ventricular systolic pressure.","CEO Han Ying stated commitment to advancing F230 through clinical development for PAH; other indications also being explored."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220018,"accession_number":"0000950170-24-056893","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gyre Therapeutics Q1 2024 revenue $27.2M, net income $9.9M; F351 Phase3 data due early 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $27.2M (+9% YoY); net income $9.9M vs $4.2M; ETUARY sales $26.9M (+10% YoY).","Cash $29.8M as of March 31, 2024 (from $33.5M at Dec 2023); expects >12 months runway.","Phase 3 F351 for CHB liver fibrosis on track; topline data expected by early 2025.","U.S. IND for F351 in NASH fibrosis expected late 2024; Phase 2a trial planned in 2025.","Acquired nintedanib rights from Jiangsu Wangao to strengthen PRC pulmonary fibrosis franchise."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":27172000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220017,"accession_number":"0001140361-24-024799","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gyre Pharma unit acquires rights to generic Nintedanib, competing drug to ETUARY, for IPF/category","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Gyre Pharmaceuticals (GYRE subsidiary) signed a comprehensive agreement with Jiangsu Wangao to acquire rights to generic Nintedanib, a competitor to ETUARY.","ETUARY sales grew 15-20% annually; IPF drug market in China expected to reach ¥127.4B by 2031 per Frost & Sullivan.","Annual sales of Nintedanib expected to exceed ¥4 billion if not included in centralized procurement system.","Acquisition enhances Gyre's leading position in pulmonary fibrosis and adds a new product for IPF and similar diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239758,"accession_number":"0001140361-24-015318","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Gyre Therapeutics regains Nasdaq compliance on audit committee composition","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on March 22, 2024, confirming regained compliance with Listing Rule 5605.","Non-compliance was previously disclosed on Jan 17, 2024, due to lack of three independent directors.","Compliance restored on March 20, 2024, with appointment of Rodney Nussbaum to Audit Committee.","No further deficiencies; shares continue trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239757,"accession_number":"0000950170-24-036135","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gyre Therapeutics reports 2023 revenue $113.5M, net loss $85.5M; ETUARY sales up 13%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 revenue of $113.5M, up from $102.3M in 2022; net loss of $85.5M vs net income of $4.3M in 2022.","ETUARY sales reached $112.1M in 2023, a 13% increase; sales team covers 35,512 hospitals across PRC.","Cash and cash equivalents $33.5M as of Dec 31, 2023 vs $25.2M end of 2022.","Phase 3 trial for F351 in CHB-associated liver fibrosis topline data expected by early 2025; U.S. Phase 2a in NASH planned for 2025.","Appointed Han Ying as CEO in January 2024; completed business combination with GNI in October 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239756,"accession_number":"0001140361-24-014493","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["5.02","1.01","7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics appoints Rodney Nussbaum to Board and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rodney Nussbaum appointed Class III director effective March 20, 2024; joins Audit Committee.","Nussbaum is a retired CPA with 40 years at Ernst & Young, KPMG, and Arthur Andersen.","Currently Managing Executive of Atago Advisory, LLC, an accounting advisory firm.","Compensation per non-employee director policy; enters standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239755,"accession_number":"0001140361-24-008051","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"GNI Group FY2023 revenue up 49% to ¥26.0B; Gyre expects Hydronidone IND in 2024; settles litigation for $385K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GNI Group FY2023 revenue ¥26,010M (+49% YoY), operating profit ¥13,108M (+851%), net profit ¥9,504M vs loss prior year.","Basic EPS ¥169.50; FY2024 guidance: revenue ¥39,566M (+52%), operating profit ¥16,286M.","Gyre expects to submit Hydronidone IND in US by end of 2024; Phase 3 trial in China last patient observation in 2024.","Gyre (as successor to Catalyst) settles shareholder litigation over business combination; pays $385K in attorneys' fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":113450000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239754,"accession_number":"0001140361-24-002903","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K/A","filed_at":"2024-01-19T23:59:59+00:00","items":["5.02","3.01","9.01"],"status":"ready","headline":"Gyre Therapeutics reports CEO transition and Nasdaq audit committee non-compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Han Ying appointed CEO effective Jan 15, 2024, succeeding retired Dr. Charles Wu.","Employment agreement: $350K base salary, annual bonus, severance with 12-month salary, COBRA, and equity acceleration.","Audit committee vacancy after Ying's departure; Nasdaq notified of non-compliance with Listing Rule 5605.","Cure period runs until earlier of next annual meeting or July 15, 2024 to restore compliance.","Dr. Renate Parry appointed Chair of Compensation Committee, replacing Dr. Han Ying."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239753,"accession_number":"0001140361-24-002118","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K/A","filed_at":"2024-01-12T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"BC 9M 2023 revenue $86.3M, net income $18.8M; Gyre Therapeutics files financials for acquired entity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BC revenue $86.3M for 9M 2023 vs $77.4M in 9M 2022 (+11.5%); net income $18.8M vs $2.3M.","Operating income $25.0M in 9M 2023, up from $7.2M in prior year period.","Cash and CDs total $46.9M as of Sep 30, 2023; equity $83.8M.","Business combination closed Oct 30, 2023; filing provides required historical financials of BC.","Pro forma combined financials also filed as Exhibit 99.2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257276,"accession_number":"0001140361-23-057889","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gyre Therapeutics appoints Dr. Han Ying as CEO effective Jan 15, 2024; Dr. Charles Wu retires for health reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Dr. Charles Wu resigns as CEO and board member effective Jan 15, 2024 due to retirement for health reasons; no disagreements.","Dr. Han Ying appointed CEO effective Jan 15, 2024; currently a director; base salary $350,000.","Dr. Ying has over 20 years experience in immunology, biotech startups, and cancer immunotherapy; previously COO of Base Therapeutics.","CEO severance provides 12 months base salary upon involuntary termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257275,"accession_number":"0001140361-23-056503","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GNI Japan revises FY2023 profit forecast up ¥6.97B on conversion of Gyre preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GNI Japan recognized ¥8,873M other income from converting Gyre Series X Preferred into 8,767,333 common shares.","Revised FY2023 operating profit forecast ¥15,744M (up 116% from ¥7,280M); profit attributable to owners ¥8,971M (up 347%).","Revised EPS forecast ¥180.42 vs previous ¥42.20; prior year ¥8.19.","Conversion based on $0.51/share closing price of CBIO on Oct 30, 2023; shares to be issued Jan 22, 2024.","Forecast excludes mark-to-market of Gyre common stock; further discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257274,"accession_number":"0001140361-23-053086","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GNI Group, Gyre's controlling shareholder, reports 9M 2023 revenue ¥20.5B (+61%), net profit ¥2.2B (+106%)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["9M 2023 revenue of ¥20,547.9M, up 61% from ¥12,761.0M in prior year.","Net profit attributable to parent ¥2,213.3M vs ¥1,076.1M, more than doubled.","Operating cash flow ¥4,443.0M, turning from negative ¥162.9M in prior year.","Total assets ¥48,468.0M, up 33% from ¥36,456.9M at prior year-end.","Basic EPS ¥46.61 (9M) vs ¥22.67; diluted EPS ¥46.13 vs ¥22.46."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257273,"accession_number":"0001140361-23-052715","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gyre Therapeutics presents Hydronidone preclinical data at AASLD; plans US clinical program in 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster at AASLD Liver Meeting (Nov 10-14, 2023) shows Hydronidone reduces liver fibrosis in mouse models.","Hydronidone inhibits hepatic stellate cell activation via Smad7-mediated TGF-β degradation.","Company expects to initiate U.S. clinical program for MASH-associated fibrosis in 2024.","Specific Smad7 knockdown in vivo blocked Hydronidone's antifibrotic effect, confirming mechanism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257272,"accession_number":"0001140361-23-051485","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GNI Group, controlling shareholder of Gyre Therapeutics, raises FY2023 forecast; revenue +3.9%, op profit +21.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue forecast raised to ¥26,267M (from ¥25,273M); operating profit to ¥7,280M (from ¥5,991M).","Net profit attributable to parent raised to ¥2,005M; basic EPS revised to ¥42.20 from ¥35.86.","ETUARY® sales in China exceeded expectations; Cullgen's Astellas alliance revenue above prior forecast.","Forex assumptions revised: US$1=¥138.24 and RMB1=¥19.62 (from ¥130.77 and ¥19.38).","Previous 2022 actuals: revenue ¥17,418M, net profit ¥388M, EPS ¥8.19."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":86302000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257271,"accession_number":"0001140361-23-051195","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"Gyre Therapeutics dismisses auditor EisnerAmper, engages Grant Thornton; CEO and CFO exit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EisnerAmper dismissed as auditor; Grant Thornton Zhitong engaged as new independent registered public accounting firm.","CEO Nassim Usman ceased as officer effective Oct 30, 2023; remains director; receives 12-month salary severance plus accelerated vesting.","Interim CFO Seline Miller ceased as officer effective Oct 30, 2023; receives 9-month salary severance plus accelerated vesting.","EisnerAmper’s prior reports included going-concern emphasis paragraphs related to convertible preferred stock cash settlement feature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257270,"accession_number":"0001140361-23-050292","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["1.01","2.01","3.02","3.03","5.03","5.01","5.02","5.05","7.01","9.01"],"status":"ready","headline":"Catalyst completes reverse merger with Beijing Continent, renames to Gyre Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["GNI USA acquired ~85.3% ownership; old Catalyst stockholders hold ~2.5%; minority holders ~12.3%.","Reverse stock split 1-for-15; authorized shares increased to 400M; ticker changes to GYRE from CBIO.","Private placement of $5.0M via convertible preferred stock and warrants to GNI USA.","New board appointed; Charles Wu named CEO, Songjiang Ma President, Ruoyu Chen Interim CFO.","Business focus shifts to organ fibrosis drug development from Beijing Continent Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257269,"accession_number":"0001140361-23-050007","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"F351 Phase III enrollment completed ahead of schedule for HBV liver fibrosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Beijing Continent completed subject enrollment for F351 Phase III trial in China, more than two months ahead of initial expectation.","Trial aims to confirm efficacy of F351 for liver fibrosis associated with chronic hepatitis B; safety comparable to Phase II.","F351 received Breakthrough Therapy designation from NMPA in 2021; top-line data expected after 52-week data collection.","BC, the trial sponsor, will become a subsidiary of Catalyst Biosciences per prior October 24 disclosure; no change to GNI consolidation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257268,"accession_number":"0001140361-23-049083","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Catalyst announces CSRC approval for business combination with Beijing Continent","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Beijing Continent Pharmaceuticals received CSRC approval on Oct 20, 2023 for the business combination.","Business Combination Agreement dated Dec 26, 2022, as amended, involves Catalyst and GNI entities.","Parties anticipate completion by the outside date as defined in the agreement.","Closing remains subject to satisfaction of other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274599,"accession_number":"0001140361-23-042067","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["1.01","3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Catalyst Biosciences stockholders approve key proposals for business combination; outside date extended to Oct 30","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders approved issuance of shares (10.5M for), conversion of preferred stock, increase authorized shares to 400M, and reverse split 1:10–1:60.","Proposals to create non-voting common stock and allow stockholder action by written consent did not pass.","Business combination outside date extended to October 30, 2023 via Second Amendment to Business Combination Agreement.","Company has not yet received required CSRC approval; no assurance transaction will close by outside date.","Certificate of Elimination filed for Series Y Preferred Stock, removing all designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274598,"accession_number":"0001140361-23-039357","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catalyst Biosciences provides H1 2023 financials of target Beijing Continent; revenue up 21% YoY","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BC revenue RMB379.3M, net profit RMB81.2M for H1 2023 vs revenue RMB312.7M, net profit RMB63.9M in H1 2022.","BC main product ETUARY for idiopathic pulmonary fibrosis; gross margin 96% in H1 2023.","BC total assets RMB806.6M, equity RMB707.8M as of June 30, 2023.","Catalyst's acquisition of indirect controlling interest in BC subject to stockholder approval; proxy mailed July 20, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":564505106.543919,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-14T23:59:59+00:00|274598"}